News Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
1.430 ^USD	-0.69%		-13.33%	-4.03%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

All News

01-26	Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology	AQ
01-06	Marker Therapeutics - Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer	AQ
01-05	Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer	AQ
11-14	Marker Therapeutics : Corporate Presentation	PU
11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-14	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates	AQ
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	Marker Therapeutics, Inc. Appoints Kathryn Penkus Corzo to Board of Directors, Effective November 1, 2025	CI
11-05	Marker Therapeutics appoints Kathryn Penkus Corzo to board of directors	RE
11-05	Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors	AQ
11-03	Marker Therapeutics, Inc. Announces Data from Phase 1 APOLLO Study to Present in Two Posters at 67Th American Society of Hematology Annual Meeting and Exposition	CI
11-03	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting	AQ
06/10/25	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program	AQ
06/10/25	Marker Therapeutics, Inc. Announces First Patient Treated in Off-The-Shelf Program	CI
28/08/25	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
26/08/25	Marker Therapeutics, Inc. - Special Call
26/08/25	Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study	MT
26/08/25	Marker Therapeutics : Corporate Presentation	PU
26/08/25	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma	AQ
14/08/25	Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
30/07/25	Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference	AQ
17/06/25	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma	AQ
04/06/25	Marker Therapeutics : Corporate Presentation	PU
29/05/25	Marker Therapeutics, Inc. - Special Call
20/05/25	Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

All News

Filters